[ 18 F]Fluorodeoxyglucose positron emission tomography ([ 18 F ] FDG PET) Characterizes Neurodegeneration Levels Across the α‐ Synucleinopathy Continuum
Movement Disorders · 2026-07 · 41 (7) · 1786-1797
DOI: 10.1002/mds.70301 ↗Kurz gefasst
Fachartikel in der Zeitschrift Movement Disorders, online erschienen am 05.04.2026. Verfasst von Beatrice Orso und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Genoa, Italy. Hauptthemen laut MEDLINE: Positron-Emission Tomography, Parkinson Disease, Synucleinopathies, REM Sleep Behavior Disorder. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero dell'Istruzione, dell'Università e della Ricerca, Ministero della Salute.
Abstract (Originalsprache)
Background [ 18 F]Fluorodeoxyglucose positron emission tomography ([ 18 F]FDG PET) represents an endorsed neurodegeneration biomarker in neuronal α‐ synucleinopathies. Idiopathic/isolated rapid eye movement (REM) sleep behavior disorder (iRBD) represents a prodromal stage of such disorders.
Objectives
To assess [ 18 F]FDG PET as a neurodegeneration biomarker, using published brain metabolic disease‐related patterns, and a regional‐based approach, across the prodromal to overt α‐ synucleinopathy continuum.
Methods
We included 83 prodromal subjects with iRBD, comprising non‐converters (n = 56) and converters (n = 27) to an overt α‐ synucleinopathy (either Parkinson's disease [PD] or dementia with Lewy bodies [DLB]) according to the last available follow‐up, and 85 subjects with PD (n = 40) and DLB (n = 45). For comparison, we enrolled a group of healthy subjects (n = 41). Participants underwent brain [ 18 F]FDG PET at baseline. Analysis of covariance was used to test the ability of previously published [ 18 F]FDG PET disease‐related patterns in characterizing neurodegeneration levels along the prodromal to overt α‐ synucleinopathy continuum, and across the motor‐predominant (parkinsonism‐first) and the cognitive‐predominant (dementia‐first) clinical trajectories. We further assessed metabolic changes using a regional‐based approach.
Results
All disease‐related patterns effectively discriminated clinical stages, from prodromal to overt α ‐synucleinopathies, with comparable performance. [ 18 F]FDG PET significantly distinguished all groups along the cognitive‐predominant pathway; whereas in the motor‐predominant pathway, converter patients were not significantly discriminated from non‐converters. Regionally, the inferior parietal, precuneus, and middle frontal areas exhibited the most prominent decrease in [ 18 F]FDG uptake with progression, alongside relative parallel progressive increases in the cerebellum, pons, parahippocampal areas, putamen, and pallidum. Conclusions [ 18 F]FDG PET disease‐related patterns efficiently characterize neurodegeneration from prodromal to overt α ‐synucleinopathy, best assessing the cognitive‐predominant (dementia‐first) pathway. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Genoa, Italy.
- Medical Psychology Unit, Department of Medicine, Institute of Neurosciences, University of Barcelona, Barcelona, Spain.
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
- Clinical Neurophysiology, IRCCS Azienda Ospedaliera Metropolitana, Genoa, Italy.
- Clinical Neurology Unit, IRCCS Azienda Ospedaliera Metropolitana, Genoa, Italy.
- Department of Radiology and Nuclear Medicine, Amsterdam UMC Location VuMC, Vijre Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands.
ORCID-Profile: Beatrice Orso, Ignacio Roura, Pietro Mattioli, Federico Massa, Monica Roascio
Förderung
- Ministero dell'Istruzione, dell'Università e della Ricerca
- Ministero della Salute
Zitieren
APA
Orso, B., Roura, I., Mattioli, P., Famà, F., Massa, F., Lorenzini, L., Brugnolo, A., Girtler, N., Losa, M., Raffa, S., Sofia, L., Roascio, M., Arnulfo, G., Morbelli, S., Pardini, M., & Arnaldi, D. (2026). [ 18 F]Fluorodeoxyglucose positron emission tomography ([ 18 F ] FDG PET) Characterizes Neurodegeneration Levels Across the α‐ Synucleinopathy Continuum. Movement Disorders, 41(7), 1786-1797. https://doi.org/10.1002/mds.70301
Vancouver
Orso B, Roura I, Mattioli P, Famà F, Massa F, Lorenzini L, et al. [ 18 F]Fluorodeoxyglucose positron emission tomography ([ 18 F ] FDG PET) Characterizes Neurodegeneration Levels Across the α‐ Synucleinopathy Continuum. Movement Disorders. 2026;41(7):1786-1797. doi:10.1002/mds.70301
BibTeX
@article{Orso2026,
author = {Orso, Beatrice and Roura, Ignacio and Mattioli, Pietro and Famà, Francesco and Massa, Federico and Lorenzini, Luigi and Brugnolo, Andrea and Girtler, Nicola and Losa, Mattia and Raffa, Stefano and Sofia, Luca and Roascio, Monica and Arnulfo, Gabriele and Morbelli, Silvia and Pardini, Matteo and Arnaldi, Dario},
title = {[ 18 F]Fluorodeoxyglucose positron emission tomography ([ 18 F ] FDG PET) Characterizes Neurodegeneration Levels Across the α‐ Synucleinopathy Continuum},
journal = {Movement Disorders},
year = {2026},
volume = {41},
number = {7},
pages = {1786--1797},
doi = {10.1002/mds.70301}
}
EUVIMED